Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Twist Bioscience Corporation (TWST) USD0.00001

Sell:$120.88 Buy:$121.07 Change: $0.15 (0.12%)
Market closed |  Prices as at close on 23 September 2021 | Switch to live prices |
Change: $0.15 (0.12%)
Market closed |  Prices as at close on 23 September 2021 | Switch to live prices |
Change: $0.15 (0.12%)
Market closed |  Prices as at close on 23 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Twist Bioscience Corporation is a synthetic biology and genomics company. The Company has developed a Twist Bioscience DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a technology that provides a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. The Company has developed multiple products derived from synthetic DNA and its versatile DNA synthesis technology. It consists of two product lines, synthetic biology tools and NGS tools, that address different needs of its customers across a range of applications, such as synthetic genes, oligo pools, SARS-CoV-2 tools, and DNA libraries. Its synthetic biology products include Synthetic genes, Clonal genes in a Twist Bioscience, Non-clonal genes, Oligonucleotide or Oligo, pools, and Oligo pools for CRISPR gene editing. The NGS products are used for diagnostic tests for various indications like SARS-CoV-2 and cancer through liquid biopsy.

Contact details

United States
+1 (408) 4100105

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$5.96 billion
Shares in issue:
49.29 million
United States
US dollar

Key personnel

  • Emily Leproust
    Chairman of the Board, President, Chief Executive Officer
  • James Thorburn
    Chief Financial Officer
  • Patrick Weiss
    Chief Operating Officer
  • Mark Daniels
    Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer and Secretary
  • William Banyai
    Senior Vice President of Research and Development, General Manager of Data Storage and Director
  • Paula Green
    Senior Vice President of Human Resources
  • Angela Bitting
    Senior Vice President - Corporate Affairs
  • Martin Kunz
    Senior Vice President - Operation
  • Erin Smith
    Senior Vice President - Government Affairs and Public Policy
  • Siyuan Chen
    Chief Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.